AI Portfolio Summary
In 2025 Q4, Krensavage Asset Management, LLC maintained a portfolio of 18 distinct positions. The most significant new addition to the portfolio was ULTRAGENYX PHARMACEU, which now represents 1.22% of the total fund value. They heavily accumulated shares in ENANTA PHARMACEUTICA, increasing their position by 30.8%. The fund also reduced its exposure to GSK PLC-SPON ADR by 64.4%.
Total Positions
18
Quarter
2025 Q4
Top Holding
UTHR (15.7%)
Top 10 Concentration
87.1%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-18 of 18
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
UTHR
UNITED THERAPEU...
|
Healthcare | 15.71% | 17.44% |
#1
Prev: #1
|
6.5 | -6,364 | -6.5% |
P
S
|
91,282 | $44,477,000 | 2014 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ENTA
ENANTA PHARMACE...
|
Healthcare | 15.41% | 10.78% |
#2
Prev: #2
|
8.0 | 651,946 | 30.8% |
P
S
|
2,766,390 | $43,626,000 | 2015 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BMRN
BIOMARIN PHARMA...
|
Healthcare | 11.02% | 9.36% |
#3
1
Prev: #4
|
7.5 | 119,336 | 29.4% |
P
S
|
524,786 | $31,188,000 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
JAZZ
JAZZ PHARMACEUT...
|
Healthcare | 10.08% | 9.42% |
#4
1
Prev: #3
|
5.5 | no change | no change |
P
S
|
167,816 | $28,529,000 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
EXEL
EXELIXIS INC
|
Healthcare | 7.64% | 9.12% |
#5
Prev: #5
|
4.1 | -25,000 | -4.8% |
P
S
|
493,526 | $21,631,000 | 2021 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
AVDL
AVADEL PHARMACE...
|
Healthcare | 6.51% | 6.22% |
#6
2
Prev: #8
|
3.1 | -100,000 | -10.5% |
P
S
|
855,860 | $18,444,000 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SNY
SANOFI-ADR
|
Healthcare | 5.54% | 6.51% |
#7
Prev: #7
|
3.2 | no change | no change |
P
S
|
323,946 | $15,698,000 | 2023 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
SUPN
SUPERNUS PHARMA...
|
Healthcare | 5.50% | 7.40% |
#8
2
Prev: #6
|
2.7 | -49,980 | -13.8% |
P
S
|
313,499 | $15,581,000 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
CAH
CARDINAL HEALTH...
|
Healthcare | 5.35% | 4.93% |
#9
1
Prev: #10
|
3.1 | no change | no change |
P
S
|
73,745 | $15,155,000 | 2022 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
INDV
INDIVIOR PLC
|
Healthcare | 4.30% | 3.49% |
#10
1
Prev: #11
|
2.7 | no change | no change |
P
S
|
339,532 | $12,182,000 | 2024 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
VNDA
VANDA PHARMACEU...
|
Healthcare | 3.68% | 2.51% |
#11
3
Prev: #14
|
2.5 | no change | no change |
P
S
|
1,180,388 | $10,411,000 | 2022 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BNTX
BIONTECH SE-ADR
|
Healthcare | 3.35% | 3.33% |
#12
Prev: #12
|
3.8 | 20,157 | 25.4% |
P
S
|
99,523 | $9,475,000 | 2024 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
GSK
GSK PLC-SPON AD...
|
Healthcare | 1.68% | 5.00% |
#13
4
Prev: #9
|
0.7 | -175,000 | -64.4% |
P
S
|
96,729 | $4,744,000 | 2025 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
RARE
ULTRAGENYX PHAR...
|
Healthcare | 1.22% | — |
#14
Prev: #—
|
4.0 | 149,634 | no change |
NEW
|
149,634 | $3,442,000 | 2025 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
REGN
REGENERON PHARM...
|
Healthcare | 1.09% | 0.96% |
#15
Prev: #15
|
1.4 | no change | no change |
P
S
|
4,000 | $3,087,000 | 2019 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
ALKS
ALKERMES PLC
|
Healthcare | 1.07% | 2.66% |
#16
3
Prev: #13
|
0.4 | -100,000 | -48.1% |
P
S
|
107,822 | $3,017,000 | 2019 Q4 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
BIIB
BIOGEN INC
|
Healthcare | 0.62% | 0.60% |
#17
1
Prev: #16
|
1.2 | no change | no change |
P
S
|
10,000 | $1,760,000 | 2019 Q1 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) | |||
|
EOLS
EVOLUS INC
|
Healthcare | 0.23% | 0.26% |
#18
1
Prev: #17
|
1.1 | no change | no change |
P
S
|
100,000 | $665,000 | 2025 Q3 | 13F Filing | 2025-12-31 | 2026-02-14 (Est.) |
Showing 1-18 of 18 holdings